Obesity insulin resistance

INCB3284 Incyte Pharmaceuticals/ Pfizer Phase Ha RA, obese insulin-resistant. It also presents mild anti-CCR5 effect. 111, 112, 124... 

For cardiovascular risk detecting and correcting factors like hypertension, obesity, insulin resistance, and type 2 diabetes or abnormal lipid profile, according to preestablished guidelines, can dramatically diminish the number of events. 

INCB3284 inhibits CCR2/MCP-1 ChemoCentryx Anti-inflammatory Rheumatoid arthritis and obese insulin-resistant patients... 

Geeraert B, Crombe F, Hulsmans M, Benhabiles N, Geuns JM, Holvoet P. (2010) Stevioside inhibits atherosclerosis by improving insulin signaling and antioxidant defense in obese insulin resistant mice. Int J Obes 34 569-577. 

Seidell, J. C. (2000). Obesity, insulin resistance and diabetes - a worldwide epidemic. British Journal of Nutrition, 3S(Suppl. 1), S5-S8. 

The hormone leptin is synthesized by adipocytes and is important in controlling body weight plasma leptin concentrations correlate with fat mass and insulin resistance. Leptin could be a link between obesity, insulin resistance syndrome, and treatment with some neuroleptic drugs. Plasma leptin concentrations are raised, regardless of weight, in patients taking clozapine (793). 

Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A Lin HM, Kales A, Chrousos GP (2000) Sleep apnea and daytime sleepiness and fatigue relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 85 1151-1158... 

Lifestyle factors have been associated with ED in both cross-sectional and longitudinal studies. In particular, obesity and sedentary lifestyle are clear-cut risk factors for ED, both in men with comorbid illnesses such as hypertension and diabetes, and especially in men without overt cardiovascular disease (50). Other lifestyle factors, such as smoking and alcohol consumption, have been implicated in some, but not all, studies to date. Intervening on cardiovascular and lifestyle factors may have broader benefits beyond restoration of erectile function. This important concept needs careful consideration, as recent studies have implicated the role of the metabolic syndrome, obesity, insulin resistance, and lack of exercise as independent risk factors for both ED and cardiovascular disease (51,52). 

Kemnitz, M. W., Elson, D. F., Roecker, E. B., Baum, S. T., Bergman, R. N., and Meglasson, M. D. (1994). Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure in Obese, Insulin-Resistant Rhesus Monkeys. Diabetes AS, 204-211. 

Reaven, G., F. Abbasi, and T. McLaughlin. 2004. Obesity, insulin resistance, and cardiovascular disease. Recent Prog. Horm. Res. 59 207-223. 

Epidemiological studies have identified a number of factors that contribute to the risk of developing cirrhosis. Regular (moderate) alcohol consumption, age older than 50 years, and male gender are examples that increase cirrhosis risk in chronic hepatitis C infection, and older age, obesity, insulin resistance or type 2 diabetes, hypertension and hyperlipidaemia in non-alcoholic steatohepatitis. 

The metabolic syndrome , characterised by abdominal obesity, insulin resistance, dislip-idaemia, low-grade inflammation, hypertension and cardiovascular disease, is a common and serious medical problem throughout the developed world that merits particular attention. Obesity is a growing problem in children. 

AA, EPA, DHA, GLA, DGLA, LXs and resolvins suppress lL-1, lL-2, lL-6, and TNF-a prodnction by T cells (110-112, 149, 176-180). This claim suggests that EFAs/PUFAs and their metabolites function as endogenous anti-inflammatory molecules and regulate immune response and thus are likely to be of benefit in obesity, insulin resistance, atherosclerosis, metabolic syndrome X, type 2 diabetes mellitus, CHD, depression, and Alzheimer s disease that are considered as diseases of low-grade systemic inflammation (1-8, 24, 120). Some beneficial actions of PUFAs in various inflammatory conditions are because of the formation of anti-inflammatory compounds such as lipoxins, resolvins, and neuroprotectin Dl. 

Kasiske BL, O Donnell MP, Keane WE. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992 19(1 suppl) 1110-5. 

A reduction in hyperinsulinaemia following metformin treatment is the most important argument for the clinical use in obese insulin-resistant Type-II... 

Metabolic syndrome, obesity, insulin resistance, dyslipidemia ] G protein signal Abnormal stability of the functional interactions of the shortened G[)3 proteins [66-68]... 

Iq32-q41 48.77 HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 600713 Cortisone reductase deficiency 2, obesity, insulin resistance... 

Metabolic effects obesity/insulin resistance/diabetes mellitus L, M, PA, P, I, G... 

Dehydroepiandrosterone (DHEA, (18)) is a major secretory product of the adrenal cortex [188] which ameliorates several metabolic abnormalities found in obese, insulin-resistant rodents. The first metabolic alteration was noted in mice carrying the viable yellow (genetic obesity) mutation [ 189] where a 0.2% dietary addition or oral administration (150-500 mg/kg, three times per week, 28 weeks) of DHEA reduced weight gain with no alteration in food consumption. Decreased accumulation of carcass triacylglycerol and decreased... 

Diabetes mellitus is a heterogeneous disease that requires various therapeutic strategies, depending on the individual. Both exogenous insulin and sul-phonylureas exert their actions by increasing local insulin concentrations at target tissues. However, in some cases, such as obese, insulin-resistant individuals, substantial circulating insulin may be present, but its actions may... 

Adams, J. M., Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R. A., Sullards, M. C., and Mandarino, L. J. 2nd. (2004). Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25-31. 

McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin resistant women and fall with weight loss. J Clin Endocrinol Metab 2006 91 1896-2000. 

---